Neurosurgeons from Germany and U.S.A. report on their clinical experience of using Nexstim NBS system

ID: 1483691
recent pressrelease next pressrelease

(Thomson Reuters ONE) -

Press release, Helsinki, 31 January 2017, at 3pm

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical
technology company with a pioneering navigated non-invasive brain stimulation
system, announces that, in a recently published clinical article, neurosurgeons
report clinical benefits of using Nexstim NBS Brain Mapping technology, for pre-
surgical localization of the motor cortex .

In a recent multi-center study at Departments of Neurosurgery at Charite
Univärsitetsmedizin, Berlin, Teknische Universität Munchen and University of
California San Francisco((1)) outcomes of brain surgery performed because of
tumor metastases in the central brain areas were compared between two
observational patient cohorts. Cohort 1 included 120 consecutive patients in
whom preoperative localization of the motor cortex in relation to the metastasis
was performed with Nexstim NBS system. Cohort 2 included 130 consecutive
patients in whom NBS motor mapping was not performed because of organizational

Results in Cohort 1 were significantly better than those in Cohort 2 both in
regard to complete tumor removal and likelihood of poor post-operative motor
function. Specifically, the NBS mapped patients had a lower rate of residual
tumor on postoperative magnetic resonance imaging (odds ratio 0.3025; 95%
confidence interval 0.1356-0.6749). Further, surgery-related paresis was less
likely in the NBS group (Cohort 1 vs. Cohort 2; patients improved in long-term
follow-up: 30.8 vs. 13.1%, unchanged: 65.8 vs. 73.8%, worse: 3.4 vs. 13.1%; p =

In the operating room, the duration of surgery was approximately 30 minutes
shorter (Cohort 1: 128.8 ± 49.4 min vs. Cohort 2: 158.0 ± 65.8 min; p = 0.0002)
and the surgical skull opening (craniotomy size) 33% smaller (Cohort 1: 16.7 ±

8.6 cm2 vs. Cohort 2: 25.0 ± 17.1 cm2; p < 0.0001) in the NBS mapped patients.

1. Krieg SM, Picht T, Sollmann N, Bährend I, Ringel F, Nagarajan SS, Meyer B,
Tarapore PE. Resection of Motor Eloquent Metastases Aided by Preoperative
nTMS-Based Motor Maps-Comparison of Two Observational Cohorts. Front Oncol.
2016 Dec 21;6:261. doi: 10.3389/fonc.2016.00261. PubMed PMID: 28066717.

Commenting on this positive clinical data, Jarmo Laine, Vice President Medical
Affairs stated: "We at Nexstim are excited about the clinical experience of
using our technology as part of the care path in these severely afflicted
patients. The results reported by the teams at these leading University
hospitals are very encouraging"

Martin Jamieson, Chairman and CEO

Further information is available on the website or by telephone:

Nexstim                                        +447715163942
Martin Jamieson, Chairman and CEO martin.jamieson(at)

About Nexstim Plc
Nexstim is a medical technology company which has pioneered its technology in
brain diagnostics with the Navigated Brain Stimulation (NBS) system. It is the
first and only FDA cleared and CE marked system based on navigated Transcranial
Magnetic Stimulation (nTMS) for pre-surgical mapping of the speech and motor
cortices of the brain. Based on the same technology platform, the Company has
developed a system called Navigated Brain Therapy (NBT®) which is CE marked for
the treatment of chronic neuropathic pain, major depression and stroke. Nexstim
shares are listed on the Nasdaq First North Finland and Nasdaq First North
Sweden. For more information please visit

Neurosurgeons from Germany and USA report on their clinical experiene:

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Nexstim Oyj via GlobeNewswire

More information: ht

Keywords (optional):

Company information / Profile:

PressRelease by


PressContact / Agency:

published by: hugin
print pressrelease  send to a friend  

Date: 01/31/2017 - 08:00
Language: English
News-ID 1483691
Character count: 2869
Firma: Nexstim Oyj
Ansprechpartner: Feedback to about Pressrelease-id:
Stadt: Helsinki


Number of hits: 127


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 54

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.